Early-Stage Life Sciences Companies in New York and Seattle Get Support Through New Collaboration with Accelerator Corporation
Developing strong syndicates to support early-stage, innovative companies is an important part of our work, which is why today we are pleased to announce a new collaboration with Accelerator Corporation, a biotechnology investment and management company that is supporting life science company formation in Seattle and New York.
New Immuno-Oncology Lung Cancer Collaboration Launched with Dana-Farber’s Belfer Institute; One of Seven New Strategic Oncology Partnerships
Today we announced a three-year collaboration with the Dana-Faber Cancer Institute’s Belfer Institute for Applied Cancer Science to determine which lung cancer patients are most likely to benefit from a new generation of immuno-oncology therapies. This agreement is one of seven new strategic oncology collaborations that we’ve recently announced, including a lymphoma program with Weill Cornell Medical College, a prostate cancer focused agreement with Aduro BioTech, and targeted antibody program agreements with the companies Bioceros, Merus, and Affimed.
Alzheimer’s disease is a looming global epidemic impacting millions of people and their families around the world. As a neuroscientist, I’ve seen first-first hand just how complex and elusive the development of better solutions to this devastating disease can be.
Rodin Secures $12.9 Million Series A Financing to Advance Epigenetic Modulators for CNS Disorders
Portfolio company Rodin Therapeutics, which is advancing its epigenetic programs for the treatment of Central Nervous System (CNS) disorders, today announced the closing of its $12.9 million Series A financing round with our corporate venture team, Johnson & Johnson Development Corporation (JJDC) and Atlas Venture.
Beyond the Bench: Creating Life Science Incubators
While the financial strength of the biotech industry continues to grow, a major barrier for starting a biopharmaceutical company remains the large upfront investment of money and time required to establish labs and other infrastructure. To explore these ideas further, we recently caught up with Kurt Hertogs, Ph.D., Head Platform Innovation & Incubator Strategy, Johnson & Johnson Innovation, London, and Melinda Richter, Head of JLabs.